Vestal Point Capital’s Agios Pharmaceuticals AGIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-450,000
Closed -$15.2M 70
2026
Q1
$15.2M Buy
450,000
+125,000
+38% +$3.54M 0.43% 58
2025
Q4
$8.85M Buy
325,000
+198,000
+156% +$6.95M 0.3% 51
2025
Q3
$5.1M Buy
+127,000
New +$4.78M 0.23% 63
2024
Q4
Sell
-760,000
Closed -$33.8M 74
2024
Q3
$33.8M Buy
+760,000
New +$34.5M 2.56% 15
2024
Q2
Sell
-325,000
Closed -$9.5M 62
2024
Q1
$9.5M Buy
+325,000
New +$8.7M 0.79% 30

Other funds holding AGIO

Vestal Point Capital's AGIO Position: Q2 2026 in Review

Vestal Point Capital sold out of Agios Pharmaceuticals (AGIO) in Q2 2026, closing a stake of 450,000 shares — an estimated $15.2M sold.

Vestal Point Capital first reported a position in AGIO in Q1 2024 and held it in 5 quarters. The position peaked at $33.8M in Q3 2024. 238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • Vestal Point Capital reported no remaining Agios Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Vestal Point Capital sold 450,000 Agios Pharmaceuticals shares in Q2 2026, an estimated $15.2M.
  • Vestal Point Capital first reported a position in Agios Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • Vestal Point Capital's Agios Pharmaceuticals position peaked at $33.8M in Q3 2024.
  • 238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.